Cardiff Oncology Inc (FRA:XE7C)
€ 2.975 -0.145 (-4.65%) Market Cap: 142.29 Mil Enterprise Value: 82.00 Mil PE Ratio: 0 PB Ratio: 2.53 GF Score: 50/100

Cardiff Oncology Inc Discusses KRAS Mutations in Cancer Transcript

Oct 14, 2020 / NTS GMT
Release Date Price: €13.1 (-4.38%)
Adrian Houser
TrialSite News - Moderator

Welcome to TrialSite News podcast series. Today we are pleased to welcome Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc. Now Cardiff Oncology, Inc. is a clinical-stage biotechnology company with a singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.

So Mark, thank you for joining our podcast today. We are honored to have you on the show.

Mark Erlander;Adrian Houser
Cardiff Oncology, Inc. - CEO;

Well, likewise, I'm also honored to be here, and thank you all for taking time out of your life to listen to this podcast. I really would like to talk to you about Cardiff Oncology and what we're doing here, and our passion for cancer patients, and what we're -- how we're doing that, and our involvement in various clinical trials with a drug that we have, that we think has a lot of promise, particularly for colorectal cancer patients as well as other cancer patients. So thank you for this opportunity.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot